Inflammation in Parkinson's disease

Abstract. Several studies of Parkinson's disease (PD) patients and experimental models of PD indicate the presence of an inflammatory process in PD. Although the primary cellular mechanisms remain to be clarified, activation of resident microglia appears to aggravate or even maintain the disease process in PD. Modulation of inflammatory mechanisms could provide a new neuroprotective therapy in PD.

[1]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[2]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[3]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[4]  B. Yankner,et al.  Inflammation and Alzheimer disease: The good, the bad, and the ugly , 2001, Nature Medicine.

[5]  P. Amouyel,et al.  Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. , 2003, Human molecular genetics.

[6]  E. Hirsch,et al.  Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.

[7]  G. Deuschl,et al.  Cerebrospinal fluid from patients with neurodegenerative and neuroninflammatory diseases: no evidence for rat glial activation in vitro , 2001, Neuroscience Letters.

[8]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[9]  O. Isacson,et al.  Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.

[10]  R. Krüger,et al.  Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease , 2002, Neuroscience Letters.

[11]  T. Moos,et al.  The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease , 1999, Neuroscience.

[12]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[13]  L. Mucke,et al.  TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. , 2001, Nature medicine.

[14]  A. Suzumura,et al.  Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease , 2000, Acta neurologica Scandinavica.

[15]  S. Mandel,et al.  Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. , 2001, Advances in neurology.

[16]  R. Magnusson,et al.  Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). , 2000, Archives of biochemistry and biophysics.

[17]  S. Yang,et al.  Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. , 2000, The Journal of pharmacology and experimental therapeutics.

[18]  Andrzej Członkowski,et al.  Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Bin Liu,et al.  Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease , 2002, Journal of neurochemistry.

[20]  I. Shoulson.  DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. , 1998, Annals of neurology.

[21]  S. Mandel,et al.  cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[22]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[23]  T. Klockgether,et al.  Inflammatory Genes Are Upregulated in Expanded Ataxin-3-Expressing Cell Lines and Spinocerebellar Ataxia Type 3 Brains , 2001, The Journal of Neuroscience.

[24]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[25]  P. Mcgeer,et al.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[26]  G. Wilkin,et al.  Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.